title: Acute renal failure after treatment with sunitinib in a patient with multiple myeloma.
abstract: Sunitinib is a multiple tyrosine kinase receptors inhibitor that is approved for the treatment of advanced renal cell carcinoma. Amongst its targets are fetal liver tyrosine kinase receptor 3 (FLT 3) and vascular endothelial growth factor receptor (VEGFR). Renal toxicity has not been reported from the trials, but several patients have been reported to develop a pre-eclampsia-like syndrome. We report the first case of acute tubular necrosis in a patient with multiple myeloma following treatment with sunitinib.
authors.affiliation: Division of Nephrology and Hypertension.
authors.forename: Nelson
authors.initials: N
authors.lastname: Leung
authors.affiliation: Division of Nephrology and Hypertension.
authors.forename: Nathan A
authors.initials: NA
authors.lastname: Saucier
authors.affiliation: Division of Hematology.
authors.forename: Steven R
authors.initials: SR
authors.lastname: Zeldenrust
authors.affiliation: Department of Pharmacology.
authors.forename: Heidi D
authors.initials: HD
authors.lastname: Gunderson
authors.affiliation: Department of Anatomic Pathology, Mayo Clinic, Rochester, MN , USA.
authors.forename: Lynn D
authors.initials: LD
authors.lastname: Cornell
keywords: acute renal failure; drug toxicity; sunitinib